UCS Pharma

PSK PHARMA is a full-cycle biopharmaceutical company, developer and manufacturer of a wide range of drugs for the treatment of socially significant diseases. Part of the RUS BIOPHARM Group of Companies.

The production complex of PSK PHARMA is located in the Dubna Special Economic Zone, produces modern drugs in more than 10 dosage forms in the following therapeutic areas:

• Pulmonology
• Rheumatology
• Haemato-oncology
• HIV
• Tuberculosis
• Diseases of the central nervous system
• GI diseases
• Cardiology
• Anesthesiology and resuscitation
• Orphan diseases

History

2023

Increase in the first quarter of natural production by 18%

On May 10, 2023, PSK Pharma announced an 18% increase in natural production in the first quarter of 2023.

The increase in production is due to several factors. These are the company's high positions in the segment of inhalation drugs - for two years in a row, PSK Pharma ranks first among suppliers of drugs for the treatment of asthma and COPD. The company's product portfolio for May 2023 includes 14 drugs reproduced in Russia. According to DSM Group analytics, by the end of 2022, 4 PSK Pharma products were included in the TOP-10 of import-substituting pharmaceutical products.

Russian developments are increasingly in demand among consumers. The requirements of the regulator are very strict, which ensures a high level of quality of Russian drugs. The local product is more accessible to patients. For example, our products are 20-30% cheaper than foreign ones. Market conditions are changing, and Russian drugs are becoming the guarantor of national drug safety. Proactively working, proactive pharmaceutical manufacturers make it possible to insure against the risk of shortages due to a decrease in the market activity of Western companies, "explained Evgenia Shapiro, CEO of PSK Pharma.

Leader among asthma and COPD drug providers according to Headway

On March 3, 2023, PSK Pharma announced that it had become the leader among suppliers of asthma and COPD drugs according to Headway.

Headway analysts calculated that the public sector in January 2022 - January 2023. for the treatment of asthma/COPD purchased drugs for 11.2 billion rubles. The leader among suppliers for the state segment in both monetary and physical terms in this period was PSK Pharma. The company delivered 2.6 million packages of 21 INN products in various dosage forms: metered-dose aerosols for inhalation, capsules with powder for inhalation and solutions for inhalation. The supply of these drugs provided the company with 29.2% of the market share in monetary terms and 20.82% in kind.

Since 2021, PSK Pharma has held the position of the national leader in the number of R3 drugs of the EphMRA level 2 therapeutic group in its portfolio.

Pulmonology is a priority area in the product portfolio of PSK Pharma. By, to data WHO non-communicable diseases (including chronic respiratory diseases) represent one of the most serious problems health care and development in this century. As noted by the chief freelance specialist pulmonologist Ministry of Health of Russia Sergei Avdeev, the prevalence of bronchial asthma in 2022 reached 7%, i.e. there is an alarming upward trend. The team of the Rus Biopharm group of companies, the most important part of which is the plant in the Dubna SEZ (PSK Pharma), will continue to develop the inhalation drugs segment, expanding the list of available drugs of this nosology.

Increasing the availability of inhalation drugs is an important issue for ensuring the well-being of society, especially during the "hot" spring-summer period. A surge in acute respiratory infections is one of the risk factors for exacerbation of chronic obstructive pulmonary diseases, especially in children. For patients with asthma and COPD, doctors recommend to be more careful in conditions of temperature swings and, even if remission of the disease is observed, not to completely refuse to use basic therapy. The growth in demand for this type of product in the "cold season" is also increasing among patients who do not suffer from chronic lung diseases, because bronchodilators are used to stop bronchospasm against the background of acute bronchitis and bronchiolitis.

The range of products manufactured by PSK Pharma includes inhaled glucocorticosteroids, which make up the main group of drugs for the treatment of asthma, as well as short and long-acting bronchodilators. The range of various molecules, dosage forms and dosages is constantly expanding, because the doctor makes the choice of a specific drug for the treatment of asthma or COPD individually, based on the characteristics of the course of the disease. As of March 2023, PSK Pharma is the only domestic manufacturer of the combined bronchodilating kit Budesonide + Formoterol, which allows you to flexibly adjust the dosage in the treatment of moderate asthma, severe asthma or COPD (if the use of Group of company Systematica is effective). The Respiforb brand has become a growth driver in the R3 group category (EphMRA Level 2) - anti-asthma and COPD drugs, according to analyst Alpharm.

These and many other inhaled drugs in the portfolio of PSK Pharma have become the "gold standard" in asthma and COPD therapy, "said Ministry of Health of the Samara Region Russia Alexander Zhestkov, chief freelance allergist-immunologist, head of the Department of General and Clinical Immunology and Allergology at Samara State University of the Ministry of Health.